---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347854"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-08-13T11:05:06+00:00"
generated_at: "2026-08-13T11:10:24.838988+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for Sagimet's denifanstat Phase 3 acne trial

## Summary
- FDA issued 'Study May Proceed' letter for Phase 3 trial of denifanstat in moderate to severe acne.
- Denifanstat is a fatty acid synthase inhibitor; trial cleared on August 13, 2026.
- Sagimet announced the IND clearance, enabling initiation of the Phase 3 study.
- No financial terms or trial design details disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-26-347854
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-08-13T11:05:06+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/0001193125-26-347854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000119312526347854/d150919d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347854
- JSON: https://secwatch.observer/filing/0001193125-26-347854.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.